Molecular imaging in prostate cancer

Journal of Cellular Biochemistry

Volumn 90, Issue 3, 2003, Pages 473-483

  Karam, Jose A ^a   Mason, Ralph P ^a   Koeneman, Kenneth S ^a   Antich, Peter P ^a   Benaim, Elie A ^a   Hsieh, Jer Tsong ^a,b  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Bioluminescence; Molecular imaging; MRI; PET; Prostate cancer; Radiolabeled antibodies; Tumor oximetry

Indexed keywords

3' FLUOROTHYMIDINE; ADENOVIRUS VECTOR; ANDROGEN; ANTIBODY 7E11 C5.3; CAPROMAB PENDETIDE IN 111; CARBON 11; CHOLINE; COPPER 64; DIACETYLBIS N4 METHYLTHIOSEMICARBAZONE; FLUORINE; FLUORINE 18; FLUOROCARBON; FLUORODEOXYGLUCOSE F 18; FLUOROETHYLCHOLINE; FLUOROMETHYLCHOLINE; FLUOROPENCICLOVIR; GADOLINIUM; HEXAFLUOROBENZENE; IODINE 131; LUCIFERASE; METRIBOLONE; PENCICLOVIR; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN ANTIBODY; PYRUVALDEHYDEBIS N4 METHYLTHIOSEMICARBAZONE; SODIUM IODIDE SYMPORTER; THIOSEMICARBAZONE DERIVATIVE; THYMIDINE DERIVATIVE; TRACER; UNCLASSIFIED DRUG;

BIOLUMINESCENCE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DRUG HALF LIFE; DRUG UPTAKE; EARLY DIAGNOSIS; FOLLOW UP; HUMAN; IMAGING SYSTEM; ISOTOPE LABELING; MALE; NON INVASIVE MEASUREMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXIMETRY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROSTATE CANCER; REVIEW; TISSUE OXYGENATION;

ANIMALS; ANTIGENS, SURFACE; CELL HYPOXIA; FLUORINE RADIOISOTOPES; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; LUMINESCENT MEASUREMENTS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; PROSTATE; PROSTATIC NEOPLASMS; RATS; SYMPORTERS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0141919707     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcb.10636     Document Type: Review

References (51)

1. Adams JY, Johnson M, Sato M, Berger F, Gambhir SS, Carey M, Iruela-Arispe ML, Wu L. 2002. Visualization of advanced human prostate cancer lesions in living mice by a targeted gene transfer vector and optical imaging. Nat Med 8:891-897.
2. American Cancer Society, Cancer Facts and Figures. 2003. www.cancer.org
3. Barentsz JO, Engelbrecht M, Jager GJ, Witjes JA, de LaRosette J, van Der Sanden BP, Huisman HJ, Heerschap A. 1999. Fast dynamic gadolinium-enhanced MR imaging of urinary bladder and prostate cancer. J Magn Reson Imaging 10:295-304.
4. Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. 1998. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: A study of 184 cases. Cancer 82:2256-2261.
5. 1H NMR spectroscopy at 9.4 T. FEBS Lett 494:112-116.
6. Contag CH, Bachmann MH. 2002. Advances in in vivo bioluminescence imaging of gene expression. Annu Rev Biomed Eng 4:235-260.
7. Dai G, Levy O, Carrasco N. 1996. Cloning and characterization of the thyroid iodide transporter. Nature 379:458-460.
8. 18F-labeled choline as an oncologic tracer for positron emission tomography: Initial findings in prostate cancer. Cancer Res 61:110-117.
9. Edinger M, Cao YA, Hornig YS, Jenkins DE, Verneris MR, Bachmann MH, Negrin RS, Contag CH. 2002. Advancing animal models of neoplasia through in vivo bioluminescence imaging. Eur J Cancer 38:2128-2136.
10. 18fluorine-labeled deoxyglucose. J Urol 155:994-998.
11. El Hilali N, Rubio N, Martinez-Villacampa M, Blanco J. 2002. Combined noninvasive imaging and luminometric quantification of luciferase-labeled human prostate tumors and metastases. Lab Invest 82:1563-1571.
12. Ellis JH, Tempany C, Sarin MS, Gatsonis C, Rifkin MD, McNeil BJ. 1994. MR imaging and sonography of early prostatic cancer: Pathologic and imaging features that influence identification and diagnosis. AJR Am J Roentgenol 162:865-872.
13. Epstein JI, Partin AW, Sauvageot J, Walsh PC. 1996. Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol 20:286-292.
14. 62Cu-PTSM and PET used for the assessment of angiotensin II-induced blood flow changes in patients with colorectal liver metastases. Eur J Nucl Med 28:99-103.
15. Freytag SO, Khil M, Stricker H, Peabody J, Menon M, DePeralta-Venturina M, Nafziger D, Pegg J, Paielli D, Brown S, Barton K, Lu M, Aguilar-Cordova E, Kim JH. 2001. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res 62:4968-4976.
16. Grauer LS, Lawler KD, Marignac JL, Kumar A, Goel AS, Wolfert RL. 1998. Identification, purification, and subcellular localization of prostate-specific membrane antigen PSM protein in the LNCaP prostatic carcinoma cell line. Cancer Res 58:4787-4789.
17. Haberkorn U. 2001. Gene therapy with sodium/iodide symporter in hepatocarcinoma. Exp Clin Endocrinol Diabetes 109:60-62.
18. 18F-fluoroethylcholine for cancer imaging with PET: Synthesis, biochemistry, and prostate cancer imaging. J Nucl Med 43:187-199.
19. Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH, de la Rosette J, Weissleder R. 2003. Noninvasive detection of clinically occult lymphnode metastasis in prostate cancer. N Engl J Med 348:2491-2499.
20. 3+ enables cell nucleus molecular imaging of prostate cancer cells: The last 600 nm. Cancer Res 62:7018-7024.
21. 3) spatial resolution. Radiology 198:795-805.
22. 19F PBSR EPI of hexafluorobenzene. Magn Reson Imaging 15:971-981.
23. 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. J Nucl Med 40:177-183.
24. Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V, Knudsen B, Bander NH. 1997. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 57:3629-3634.
25. 19F NMR of perfluorocarbons. Artif Cells Blood Substit Immobil Biotechnol 22:1141-1153.
26. Mason RP, Antich PP, Babcock EE, Constantinescu A, Peschke P, Hahn EW. 1994. Non-invasive determination of tumor oxygen tension and local variation with growth. Int J Radiat Oncol Biol Phys 29:95-103.
27. Mason RP, Hunjan S, Le D, Constantinescu A, Barker BR, Wong PS, Peschke P, Hahn EW, Antich PP. 1998. Regional tumor oxygen tension: Fluorine echo planar imaging of hexafluorobenzene reveals heterogeneity of dynamics. Int J Radiat Oncol Biol Phys 42:747-750.
28. Mathews D, Oz OK. 2002. Positron emission tomography in prostate and renal cell carcinoma. Current Opinion in Urology 12:381-385.
29. Norberg M, Egevad L, Holmberg L, Sparen P, Norlen BJ, Busch C. 1997. The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer. Urology 50:562-566.
30. 11C-acetate PET imaging of prostate cancer. J Nucl Med 43:181-186.
31. Pantuck AJ, Berger F, Zisman A, Nguyen D, Tso CL, Matherly J, Gambhir SS, Belldegrun AS. 2002. CL1-SR39: A noninvasive molecular imaging model of prostate cancer suicide gene therapy using positron emission tomography. J Urol 168:1193-1198.
32. Parivar F, Hricak H, Shinohara K, Kurhanewicz J, Vigneron DB, Nelson SJ, Carroll PR. 1996. Detection of locally recurrent prostate cancer after cryosurgery: Evaluation by transrectal ultrasound, magnetic resonance imaging, and three-dimensional proton magnetic resonance spectroscopy. Urology 48:594-599.
33. 18F]fluorodeoxyglucose-positron emission tomography. J Urol 169:1337-1340.
34. Raj GV, Partin AW, Polascik TJ. 2002. Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy. Cancer 94:987-996.
35. Rosenthal SA, Haseman MK, Polascik TJ. 2001. Utility of capromab pendetide (ProstaScint) imaging in the management of prostate cancer. Tech Urol 7:27-37.
36. Scheffold C, Kornacker M, Scheffold YC, Contag CH, Negrin RS. 2002. Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab′)(2)HER2xCD3. Cancer Res 62:5785-5791.
37. Scheidler J, Hricak H, Vigneron DB, Yu KK, Sokolov DL, Huang LR, Zaloudek CJ, Nelson SJ, Carroll PR, Kurhanewicz J. 1999. Prostate cancer: Localization with three-dimensional proton MR spectroscopic imaging-clinicopathologic study. Radiology 213:473-480.
38. Seltzer MA, Barbaric Z, Belldegrun A, Naitoh J, Dorey F, Phelps ME, Gambhir SS, Hoh CK. 1999. Comparison of helical computerized tomography, positron emission tomography, and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. J Urol 162:1322-1328.
39. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, Obradovich JE, Muzik O, Mangner TJ. 1998. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 4:1334-1336.
40. Shreve PD, Grossman HB, Gross MD, Wahl RL. 1996. Metastatic prostate cancer: Initial findings of PET with 2-deoxy-2-[F-18] fluoro-D-glucose. Radiology 199:751-756.
41. Smith-Jones PM, Vallabhajosula S, Navarro V, Bastidas D, Goldsmith SJ, Bander NH. 2003. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: Preclinical studies in nude mice bearing LNCaP human prostate tumor. J Nucl Med 44:610-617.
42. Song SK, Qu Z, Garabedian EM, Gordon JI, Milbrandt J, Ackerman JJ. 2002. Improved magnetic resonance imaging detection of prostate cancer in a transgenic mouse model. Cancer Res 62:1555-1558.
43. Spitzweg C, Zhang S, Bergert ER, Castro MR, McIver B, Heufelder AE, Tindall DJ, Young CY, Morris JC. 1999. Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines. Cancer Res 59:2136-2141.
44. Spitzweg C, O'Connor MK, Bergert ER, Tindall DJ, Young CY, Morris JC. 2000. Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter. Cancer Res 60:6526-6530.
45. Sweat SD, Pacelli A, Murphy GP, Bostwick DG. 1998. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 52:637-640.
46. Taylor NJ, Baddeley H, Goodchild KA, Powell ME, Thoumine M, Culver LA, Stirling JJ, Saunders MI, Hoskin PJ, Phillips H, Padhani AR, Griffiths JR. 2001. BOLD MRI of human tumor oxygenation during carbogen breathing. J Magn Reson Imaging 14:156-163.
47. Van Der Graaf M, Schipper RG, Oosterhof GO, Schalken JA, Verhofstad AA, Heerschap A. 2000. Proton MR spectroscopy of prostatic tissue focused on the detection of spermine, a possible biomarker of malignant behavior in prostate cancer. MAGMA 10:153-159.
48. Van Sande J, Massart C, Beauwens R, Schoutens A, Costagliola S, Dumont JE, Wolff J. 2003. Anion selectivity by the sodium iodide symporter. Endocrinology 144:247-252.
49. Yu KK, Scheidler J, Hricak H, Vigneron DB, Zaloudek CJ, Males RG, Nelson SJ, Carroll PR, Kurhanewicz J. 1999. Prostate cancer: Prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiology 213:481-488.
50. Zhao D, Constantinescu A, Hahn EW, Mason RP. 2002. Differential oxygen dynamics in two diverse Dunning prostate R3327 rat tumor sublines (MAT-Lu and HI) with respect to growth and respiratory challenge. Int J Radiat Oncol Biol Phys 53:744-756.
51. Zhao D, Constantinescu A, Chang CH, Hahn EW, Mason RP. 2003. Correlation of tumor oxygen dynamics with radiation response of the Dunning prostate R3327-HI tumor. Radiat Res 159:621-631.